Intelligence · Clinical pipeline
Oncology R&D Pipeline
Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.
Quick answer
Oncology: NovaPharmaNews indexes 5,539 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.
Top sponsors
- First People's Hospital 474 programs
- Chinese Academy of 400 programs
- United Therapeutics Europe 219 programs
- George Institute for 172 programs
- Takeda 163 programs
- HOFFMANN-LA ROCHE 144 programs
- AstraZeneca 143 programs
- MSD Merck Sharp 131 programs
- Regeneron UK 128 programs
- Anaxis Pharma 125 programs
- Telethon Foundation 113 programs
- Novartis India 110 programs
Pipeline programs
-
Toripalimab
Coherus Oncology
Nasopharyngeal Cancer Recurrent
1 trial -
Tramadol HCI/acetaminophen
Janssen-Cilag Pty Ltd
Cancer
1 trial -
Trastuzumab Rezetecan
The First People's Hospital of Lianyungang
Breast Cancer
1 trial -
V0001699
Disc Medicine
Oral cancer
1 trial -
Vemurafenib
Hoffmann-La Roche
Neoplasms
1 trial -
Venetoclax
AbbVie
Acute Myeloid Leukemia (AML)
1 trial -
Xiang Sha Liu Jun Zi Decoction dry powder
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Hepatocellular Carcinoma
1 trial -
Xtandi - 40 mg soft capsules
The George Institute
PROSTATE CANCER
1 trial -
aspirin and/or clopidogrel
Takeda
Early Gastric Cancer
1 trial -
crizotinib
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Systemic Anaplastic Large-Cell Lymphoma
1 trial -
dabrafenib
Novartis Pharmaceuticals
Melanoma
1 trial -
docetaxel
Hoffmann-La Roche
Breast Cancer
2 trials -
first-line scheme+compound kushen injection
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Advanced Colorectal Carcinoma
1 trial -
inotuzumab ozogamicin-dose level 2
Pfizer
Leukemia
1 trial -
neoadjuvant therapy
The First People's Hospital of Lianyungang
Hepatocellular Carcinoma Resectable
1 trial -
silk suture
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Breast Cancer
1 trial -
temsirolimus
Pfizer
Non-Hodgkin's Lymphoma
1 trial -
trastuzumab [Herceptin]
Hoffmann-La Roche
Gastric Cancer
1 trial -
1.0 /2024.05.01
The First People's Hospital of Lianyungang
Gastrointestinal Stromal Tumors
1 trial -
18F-FDG
The First People's Hospital of Lianyungang
Tumor, Solid
1 trial -
18F-P3BZA
Xijing Hospital
Melanoma
1 trial -
2023-SR-508
The First People's Hospital of Lianyungang
Acute Myeloid Leukemia
1 trial -
2024474
The First People's Hospital of Lianyungang
Primary Central Nervous System Lymphoma (PCNSL)
1 trial -
2025XJSLL-10
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Prostate Cancer (Diagnosis)
1 trial -
68Ga-DOTA-NT-20.3
The First People's Hospital of Lianyungang
Pancreatic Ductal Adenocarcinoma
1 trial -
68Ga-Her2-affibody
The First People's Hospital of Lianyungang
Neoplasms
1 trial -
89Zr-KN035
The First People's Hospital of Lianyungang
Solid Tumor, Adult
1 trial -
89Zr-trastuzumab
United Therapeutics Europe Ltd
Breast Cancer Metastases
1 trial -
AVN944
Vertex Pharmaceuticals (Australia) Pty.
Refractory Solid Tumors
1 trial -
Abbreviated non-contrast MRI of the liver
Hospital Authority, Hong Kong
Hepatocellular Carcinoma
1 trial -
Acalabrutinib
The First People's Hospital of Lianyungang
Chronic Lymphocytic Leukemia
1 trial -
Accelerated partial breast irradiation
Universal Integrated
Breast Cancer
1 trial -
Accurate Prediction Artificial Intelligence Models
The First People's Hospital of Lianyungang
Prostate Cancer
1 trial -
Akkermansia Probiotics
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Colo-rectal Cancer
1 trial -
Albumin paclitaxel/neutrophil drug
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Breast Cancer
1 trial -
Albumin-Bound Paclitaxel
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Gastric Carcinoma
1 trial -
Anlotinib hydrochloride
The First People's Hospital of Lianyungang
Non-Small-Cell Lung Cancer
2 trials -
Anti-HER2 CAR-T cells
The First People's Hospital of Lianyungang
HER2-positive Advanced Malignant Solid Tumors
1 trial -
Anti-PD1
Hospital Authority, Hong Kong
Nasopharyngeal Carcinoma (NPC)
1 trial -
Artificial Intelligence Enabled Transvaginal Ultrasound Imaging algorithm
The First People's Hospital of Lianyungang
Ovarian Cancer
1 trial -
BCL regimen
The First People's Hospital of Lianyungang
Peripheral T-cell Lymphoma
1 trial -
Biobran supplementation
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Breast Cancer Stages I
1 trial -
Boost to the tumour bed
United Therapeutics Europe Ltd
Early Breast Cancer
1 trial -
Breast MRI interpretation
The First People's Hospital of Lianyungang
Breast Cancer
1 trial -
Breztri Aerosphere
The First People's Hospital of Lianyungang
Lung Cancer, Nonsmall Cell
1 trial -
Bromocriptin 2.5mg, 2-3 times a day
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Pituitary Tumor
1 trial -
CAR-CD19 T cell
The First People's Hospital of Lianyungang
B Cell Lymphoma
1 trial -
CAR-T cells
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Philadelphia Positive Acute Lymphoblastic Leukemia
1 trial
Frequently asked questions
How many oncology pipeline programs are tracked?
5,539 programs match this therapeutic area based on indication text, program name, and registry metadata.
Where does pipeline data come from?
ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.